

September 24, 2025

Dear Prader-Willi Syndrome Community,

Today Acadia announced top-line results from the company's Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin in patients with hyperphagia in Prader-Willi syndrome. Intranasal carbetocin did not demonstrate significant improvement over placebo on the study's primary or secondary measures.

We are deeply disappointed by the results of this clinical trial, knowing the incredible need for treatment options to address hyperphagia in Prader-Willi syndrome, and are profoundly grateful to the patients, families, and investigators who have participated in this clinical trial for their dedication and contributions to advancing scientific understanding.

Acadia does not intend to investigate intranasal carbetocin further and we plan to share an organized plan to discontinue the open-label extension trial with our study investigators this week. For those who are participating in the ongoing trial, please reach out to your study coordinator or investigator for additional information next week.

We are committed to sharing a summary of the data at a future scientific forum to ensure our efforts contribute to future scientific understanding of Prader-Willi syndrome.

The heart and passion of this community have inspired us, and we value the relationships that we have formed with you. We sincerely appreciate the opportunity to learn from you and to share in your journey.

All our best,

Acadia